drugset / Trial / NCT01605734
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
TACE is widely used in patients with unresectable HCC. However, it is a non-curative approach; thus ,strategies to further improve the survival of these patients are needed. Sorafenib is regarded as standard treatment for advanced HCC. It is the first systemic therapy to demonstrate a significant survival benefit in HCC patients.The hypothesis is that the combination of TACE with sorafenib could improve the survival of patients with unresectable HCC.
Timeline
- Start
- 2012-07
- Primary completion
- 2013-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 800 mg | Oral |